BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y, Hatooka M, Morio K, Nakahara T, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2018;48:51-58. [PMID: 28342265 DOI: 10.1111/hepr.12895] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 11.2] [Reference Citation Analysis]
Number Citing Articles
1 O'Leary JG. Portal Vein Thrombosis Prediction: Rebalanced Coagulation and Rethinking Anticoagulation. Liver Transpl 2019;25:1741-2. [PMID: 31609543 DOI: 10.1002/lt.25661] [Reference Citation Analysis]
2 Mori A, Arimoto A, Hamaguchi Y, Kajiwara M, Nakajima A, Kanaya S. Risk Factors and Outcome of Portal Vein Thrombosis After Laparoscopic and Open Hepatectomy for Primary Liver Cancer: A Single-Center Experience. World J Surg 2020;44:3093-9. [PMID: 32394012 DOI: 10.1007/s00268-020-05565-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
3 Riva N, Ageno W. Timing of Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: An Italian Internist's Perspective. J Transl Int Med 2018;6:6-10. [PMID: 29607297 DOI: 10.2478/jtim-2018-0002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv Ther 2020;37:1910-32. [PMID: 32285340 DOI: 10.1007/s12325-020-01307-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
5 Elhosseiny S, Al Moussawi H, Chalhoub JM, Lafferty J, Deeb L. Direct Oral Anticoagulants in Cirrhotic Patients: Current Evidence and Clinical Observations. Can J Gastroenterol Hepatol. 2019;2019:4383269. [PMID: 30792971 DOI: 10.1155/2019/4383269] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Cohen O, Caiano LM, Tufano A, Ageno W. Cancer-Associated Splanchnic Vein Thrombosis. Semin Thromb Hemost 2021. [PMID: 34116580 DOI: 10.1055/s-0040-1722607] [Reference Citation Analysis]
7 Valeriani E, Di Nisio M, Riva N, Cohen O, Porreca E, Senzolo M, De Gottardi A, Magaz M, Garcia-Pagan JC, Ageno W. Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Thromb Haemost 2021;121:867-76. [PMID: 33525037 DOI: 10.1055/s-0040-1722192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hoolwerf EW, Kraaijpoel N, Büller HR, van Es N. Direct oral anticoagulants in patients with liver cirrhosis: A systematic review. Thromb Res 2018;170:102-8. [PMID: 30153564 DOI: 10.1016/j.thromres.2018.08.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
9 Naymagon L. Venous thrombosis of the liver: current and emerging concepts in management. Transl Res 2020;225:54-69. [PMID: 32407789 DOI: 10.1016/j.trsl.2020.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
10 Gîrleanu I, Trifan A, Stanciu C, Sfarti C. Portal vein thrombosis in cirrhotic patients - it is always the small pieces that make the big picture. World J Gastroenterol 2018; 24(39): 4419-4427 [PMID: 30356984 DOI: 10.3748/wjg.v24.i39.4419] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
11 Faccia M, Ainora ME, Ponziani FR, Riccardi L, Garcovich M, Gasbarrini A, Pompili M, Zocco MA. Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. World J Gastroenterol 2019; 25(31): 4437-4451 [PMID: 31496623 DOI: 10.3748/wjg.v25.i31.4437] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
12 Koh JH, Liew ZH, Ng GK, Liu HT, Tam YC, De Gottardi A, Wong YJ. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00408-4. [PMID: 34393072 DOI: 10.1016/j.dld.2021.07.039] [Reference Citation Analysis]
13 Wang L, Guo X, Xu X, De Stefano V, Plessier A, Noronha Ferreira C, Qi X. Anticoagulation Favors Thrombus Recanalization and Survival in Patients With Liver Cirrhosis and Portal Vein Thrombosis: Results of a Meta-Analysis. Adv Ther 2021;38:495-520. [PMID: 33155180 DOI: 10.1007/s12325-020-01550-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Endo K, Oikawa T, Kakisaka K, Tamura A, Ehara S, Takikawa Y. The impact of portal vein thrombosis on the prognosis and liver function of nonmalignant cirrhotic patients. Scandinavian Journal of Gastroenterology 2018;53:1340-6. [DOI: 10.1080/00365521.2018.1503327] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hayashi T, Takatori H, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Shimakami T, Arai K, Kitamura K, Kawaguchi K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Toyama T, Okumura K, Kozaka K, Kaneko S. Danaparoid sodium-based anticoagulation therapy for portal vein thrombosis in cirrhosis patients. BMC Gastroenterol 2019;19:217. [PMID: 31842768 DOI: 10.1186/s12876-019-1140-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
16 Jo HG, Kim YR, Cho EY. [The Effect of Anticoagulant in Patients with Cirrhosis Associated with Acute Portal Vein Thrombosis]. Korean J Gastroenterol 2021;78:177-82. [PMID: 34565787 DOI: 10.4166/kjg.2021.050] [Reference Citation Analysis]
17 Qamar A, Antman EM, Ruff CT, Nordio F, Murphy SA, Grip LT, Greenberger NJ, Yin OQP, Choi Y, Lanz HJ, Mercuri MF, Braunwald E, Giugliano RP. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease. J Am Coll Cardiol 2019;74:179-89. [PMID: 31296289 DOI: 10.1016/j.jacc.2019.04.061] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
18 McMurry HS, Jou J, Shatzel J. The hemostatic and thrombotic complications of liver disease. Eur J Haematol 2021. [PMID: 34258797 DOI: 10.1111/ejh.13688] [Reference Citation Analysis]
19 Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. [PMID: 33219529 DOI: 10.1002/hep.31646] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 28.0] [Reference Citation Analysis]
20 Nisly SA, Mihm AE, Gillette C, Davis KA, Tillett J. Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis. J Thromb Thrombolysis 2021. [PMID: 33728575 DOI: 10.1007/s11239-021-02424-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chen S, Pürerfellner H, Meyer C, Sommer P, Galindo Kiuchi M, Martinek M, Futyma P, Zanchi S, Zhu L, Schratter A, Wang J, Acou WJ, Liu S, Ling Z, Yin Y, Ouyang F, Chun JKR, Schmidt B. Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of > 20000 patients. Eur Heart J Cardiovasc Pharmacother 2021:pvab032. [PMID: 33871577 DOI: 10.1093/ehjcvp/pvab032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Galante A, De Gottardi A. Portal vein thrombosis: an overview of current treatment options. Acta Gastroenterol Belg 2021;84:327-32. [PMID: 34217184 DOI: 10.51821/84.2.327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Valla DC. Recent developments in the field of vascular liver diseases. Liver Int 2020;40 Suppl 1:142-8. [PMID: 32077611 DOI: 10.1111/liv.14348] [Reference Citation Analysis]
24 Mohan BP, Aravamudan VM, Khan SR, Ponnada S, Asokkumar R, Adler DG. Treatment response and bleeding events associated with anticoagulant therapy of portal vein thrombosis in cirrhotic patients: Systematic review and meta-analysis. Ann Gastroenterol 2020;33:521-7. [PMID: 32879600 DOI: 10.20524/aog.2020.0503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kawata E, Siew DA, Payne JG, Louzada M, Kovacs MJ, Lazo-Langner A. Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes. Thromb Res 2021;202:90-5. [PMID: 33798804 DOI: 10.1016/j.thromres.2021.03.018] [Reference Citation Analysis]
26 Zhou T, Sun X, Zhou T, Li Y, Chen X, Cheng B, Gao Y. Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00228. [PMID: 32858573 DOI: 10.14309/ctg.0000000000000228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
27 Steuber TD, Howard ML, Nisly SA. Direct Oral Anticoagulants in Chronic Liver Disease. Ann Pharmacother 2019;53:1042-9. [PMID: 30947523 DOI: 10.1177/1060028019841582] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
28 Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral Anticoagulation in Patients With Liver Disease. J Am Coll Cardiol 2018;71:2162-75. [PMID: 29747837 DOI: 10.1016/j.jacc.2018.03.023] [Cited by in Crossref: 58] [Cited by in F6Publishing: 46] [Article Influence: 19.3] [Reference Citation Analysis]
29 Yao W, Feng Y, Liu T, Li W, Zhang M, Yao Y, Wu S. Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: A randomized clinical trial. EXCLI J 2021;20:537-49. [PMID: 33883982 DOI: 10.17179/excli2020-3120] [Reference Citation Analysis]
30 De Maria C, Galante A, Fasoli A, De Gottardi A. When and how to use direct oral anticoagulants in patients with advanced chronic liver disease? Curr Opin Pharmacol 2021;60:111-6. [PMID: 34403992 DOI: 10.1016/j.coph.2021.07.006] [Reference Citation Analysis]
31 Primignani M, Tosetti G. Direct oral anticoagulants for portal vein thrombosis in cirrhosis: Good news from meta-analysis? Dig Liver Dis 2022;54:54-5. [PMID: 34688574 DOI: 10.1016/j.dld.2021.09.018] [Reference Citation Analysis]
32 Menichelli D, Ronca V, Di Rocco A, Pignatelli P, Marco Podda G; CAR. Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis. Eur J Clin Invest 2021;51:e13397. [PMID: 32895926 DOI: 10.1111/eci.13397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Ilcewicz HN, Martello JL, Piechowski K. Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis. Eur J Gastroenterol Hepatol 2021;33:911-6. [PMID: 33079786 DOI: 10.1097/MEG.0000000000001958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
34 O’leary JG, Greenberg CS, Patton HM, Caldwell SH. AGA Clinical Practice Update: Coagulation in Cirrhosis. Gastroenterology 2019;157:34-43.e1. [DOI: 10.1053/j.gastro.2019.03.070] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 27.0] [Reference Citation Analysis]
35 Cohen O, Ageno W. The safety of anticoagulant therapy in the treatment of splanchnic vein thrombosis associated with acute pancreatitis. Intern Emerg Med 2020;15:929-31. [PMID: 32285348 DOI: 10.1007/s11739-020-02336-w] [Reference Citation Analysis]
36 Riva N, Ageno W. Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. J Clin Med 2020;9:E743. [PMID: 32164214 DOI: 10.3390/jcm9030743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
37 Williams C, Stewart E, Conzen KD, Wolf S, Tran TT. Dabigatran Reversal With Idarucizumab in 2 Patients With Portal Vein Thrombosis Undergoing Orthotopic Liver Transplantation. Semin Cardiothorac Vasc Anesth 2021;25:200-7. [DOI: 10.1177/1089253220982183] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Salim S, Ekberg O, Elf J, Zarrouk M, Gottsäter A, Acosta S. Clinical implications of CT findings in mesenteric venous thrombosis at admission. Emerg Radiol 2018;25:407-13. [DOI: 10.1007/s10140-018-1601-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
39 Suda T, Takatori H, Hayashi T, Horii R, Nio K, Terashima T, Iida N, Kitahara M, Shimakami T, Arai K, Yamashita T, Yamashita T, Mizukoshi E, Honda M, Okumura K, Kozaka K, Kaneko S. Investigation of Thrombosis Volume, Anticoagulants, and Recurrence Factors in Portal Vein Thrombosis with Cirrhosis. Life (Basel) 2020;10:E177. [PMID: 32899804 DOI: 10.3390/life10090177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Toyoda J, Morioka D, Horii N, Nakayama G, Oyama N, Asano F, Izumisawa Y, Miura M, Sato Y, Endo I. Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report. J Med Case Rep 2021;15:52. [PMID: 33563326 DOI: 10.1186/s13256-020-02651-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Valeriani E, Di Nisio M, Riva N, Cohen O, Garcia-Pagan JC, Magaz M, Porreca E, Ageno W. Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood 2021;137:1233-40. [PMID: 32911539 DOI: 10.1182/blood.2020006827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
42 Senzolo M, Garcia-Tsao G, García-Pagán JC. Current knowledge and management of portal vein thrombosis in cirrhosis. J Hepatol 2021;75:442-53. [PMID: 33930474 DOI: 10.1016/j.jhep.2021.04.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
43 Riva N, Ageno W. Direct oral anticoagulants for unusual-site venous thromboembolism. Res Pract Thromb Haemost 2021;5:265-77. [PMID: 33733025 DOI: 10.1002/rth2.12480] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Ogawa S, Yamamoto A, Jogo A, Nakano MM, Kageyama K, Sohgawa E, Nishida N, Kaminou T, Miki Y. Splenic Vein Diameter is a Risk Factor for the Portal Venous System Thrombosis After Partial Splenic Artery Embolization. Cardiovasc Intervent Radiol 2021;44:921-30. [PMID: 33474605 DOI: 10.1007/s00270-020-02751-8] [Reference Citation Analysis]
45 Gupta S, Hidalgo J, Singh B, Iyer A, Yang Y, Short A, Singh S, Bhatt H, Gupta S. Usage of Direct Acting Oral Anticoagulants in Cirrhotic and Non-Cirrhotic Portal Vein Thrombosis: A Systematic Review. Cureus 2021;13:e16922. [PMID: 34367844 DOI: 10.7759/cureus.16922] [Reference Citation Analysis]
46 Ng CH, Tan DJH, Nistala KRY, Syn N, Xiao J, Tan EXX, Woo FZ, Chew NWS, Huang DQ, Dan YY, Sanyal AJ, Muthiah MD. A network meta-analysis of direct oral anticoagulants for portal vein thrombosis in cirrhosis. Hepatol Int 2021;15:1196-206. [PMID: 34417718 DOI: 10.1007/s12072-021-10247-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Intagliata NM, Caldwell SH, Tripodi A. Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. Gastroenterology 2019; 156: 1582-1599. e1. [PMID: 30771355 DOI: 10.1053/j.gastro.2019.01.265] [Cited by in Crossref: 79] [Cited by in F6Publishing: 65] [Article Influence: 26.3] [Reference Citation Analysis]
48 Valeriani E, Riva N, Di Nisio M, Ageno W. Splanchnic Vein Thrombosis: Current Perspectives. Vasc Health Risk Manag 2019;15:449-61. [PMID: 31695400 DOI: 10.2147/VHRM.S197732] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
49 Iida H, Miyake T, Tani M, Tanaka T, Kawakami K, Ikuno Y, Mandai R, Shimizu T. Cerebellar hemorrhage in patients treated with edoxaban for portal vein thrombosis after hepatobiliary surgery: a report of two cases. Surg Case Rep 2020;6:319. [PMID: 33305345 DOI: 10.1186/s40792-020-01086-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Lapumnuaypol K, DiMaria C, Chiasakul T. Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis. QJM 2019;112:605-10. [PMID: 31135040 DOI: 10.1093/qjmed/hcz127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
51 Rupoli S, Fiorentini A, Morsia E, Svegliati-Baroni G, Micucci G, Maroni L, Garvey KB, Fiorentini A, Riva A, Da Lio L, Benedetti A, Offidani M, Olivieri A, Giuseppe T. Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience. Vasc Health Risk Manag 2021;17:619-29. [PMID: 34594107 DOI: 10.2147/VHRM.S310615] [Reference Citation Analysis]
52 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
53 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Mort JF, Davis JPE, Mahoro G, Stotts MJ, Intagliata NM, Northup PG. Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis. Clin Gastroenterol Hepatol 2021;19:1436-42. [PMID: 32777555 DOI: 10.1016/j.cgh.2020.08.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
55 Fukui R, Hira D, Kunitsu Y, Isono T, Tabuchi Y, Ikuno Y, Ueshima S, Itoh H, Tanaka T, Terada T. High incidence of major bleeding with off-label use of edoxaban. J Clin Biochem Nutr 2021;69:311-6. [PMID: 34857995 DOI: 10.3164/jcbn.21-9] [Reference Citation Analysis]
56 Chen H, Lei J, Liang S, Luo G, Deng M, Lü M. Safety and Efficacy of Anticoagulation in Patients with Cirrhosis: A Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:8859602. [PMID: 34007837 DOI: 10.1155/2021/8859602] [Reference Citation Analysis]
57 Hayashi M, Sugaya T, Fujita M, Nakamura J, Imaizumi H, Abe K, Takahashi A, Takagi T, Hikichi T, Ohira H. Sigmoid Colon Varices due to Massive Thrombosis of a Noncirrhotic Extrahepatic Portosystemic Shunt. Intern Med 2020;59:2705-10. [PMID: 32669497 DOI: 10.2169/internalmedicine.4925-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]